Captor Therapeutics Sa · GPW:CTX
Captor Therapeutics Sa — H1 2024 Earnings Presentation
24 slides from Captor Therapeutics Sa's earnings presentation, Sep 10, 2024
Slide 1: H1 2024 Results
H1 2024 Results 1
Slide 2: H1 2024 update – top line
H1 2024 update – top line • Captor submitted the application for clinical trial authorisation in Europe for the CT-01 project in August 2024 • Site recruitment to the CT-01 clinical study in liver cancer patients has gone exceptionally well • CT-02 (NEK7) and CT-03 (MCL-1) continue to advance • In-v
Slide 3: The Clinical Team taking CT-01 forward
The Clinical Team taking CT-01 forward Andrew Saunders DPM, FFPM Robert Dyjas, M.D. Ph.D. Chief Medical Officer Head of Medical Affairs and Clinical Development • MB BCh BAO BA, Medicine, Trinity College Dublin • Specialization in internal diseases • FFPM, Royal College of Physicians, • PhD in medic
Slide 4: Fully owned pipeline
Fully owned pipeline Program Primary Indications Modality Discovery Preclinical* IND Filing Phase IA / IB Phase II Target GSPT1 CT-01 GSPT1 Hepatocellular carcinoma, MG Lung cancer, NET tumors NEK7 CT-02 NEK7 Autoimmunity, CNS, MG Metabolism, Oncology CT-03 MCL-1 MCL-1 Liquid & solid tumors BIFD CT-
Slide 5: Clinical Research Organisation
Clinical Research Organisation ICON Clinical Research Limited (Dublin, Ireland) World leader in the field of providing innovative solutions in the healthcare system and CRO (Clinical Research Organization) Design and conduct of the first phase of clinical trials of a new, innovative anticancer drug
Slide 6: CT-01: First-in-Class GSPT1 Targeted Degrader for Hepatocellular Carcinoma (HCC)
CT-01: First-in-Class GSPT1 Targeted Degrader for Hepatocellular Carcinoma (HCC) 6
Slide 7: CT-01: Multi-target GSPT1, NEK7 & SALL4 degrader
CT-01: Multi-target GSPT1, NEK7 & SALL4 degrader Lung cancer GSPT1 degradation leads to an Integrated Stress Response 400k patients and induction of apoptosis in HCC cells SALL4 is expressed in fetal liver, silenced in adults, but often re-expressed in HCC and correlates with poor prognosis NEK7 deg
Slide 8: Liver cancer
Liver cancer Liver cancer • Fifth most common cancer • Second most frequent cause of cancer-related death globally • 905,000 new cases and 830,000 deaths per year • 7% of all cancers Hepatocellular Carcinoma (HCC) • Accounts for approximately 90% of primary liver cancers • Constitutes a major global
Slide 9: Epidemiology of Hepatocellular carcinoma
Epidemiology of Hepatocellular carcinoma 9
Slide 10: HCC: current standard of care and opportunity
HCC: current standard of care and opportunity Survival Benefit vs Line Therapy FDA Approval Sorafenib Unresectable / metastatic HCC 1 +5.8 months1 No prior therapy 1 +2.7 months2 Unresectable HCC 1/2 -3 Unresectable HCC Unresectable HCC 2 +1.7 months4 (Post sorafenib) Unresectable HCC 2 +2.2 months5
Slide 11: A key advantage of CT-01 for hepatocellular carcinoma
A key advantage of CT-01 for hepatocellular carcinoma ORAL ADMINISTRATION BIOTRANSFORMATION Oral drugs pass through the liver before entering the systemic LIVER circulation HEPATIC PORTAL VEIN This should result in higher INTESTINES concentration of CT-01 active drug The first step of CT-01 in HCC c
Slide 12: CT-01: Progress to the clinic
CT-01: Progress to the clinic 12
Slide 13: Status: CT-01
Status: CT-01 • Initial indication • Hepatocellular carcinoma • Degradation profile Molecular • GSPT1, NEK7 Glue • Activated in diseased liver & lung • Differentiation from other GSPT1 degraders (BMS, Monte Rosa): potential for improved therapeutic window • Oral pro-drug that goes to the target orga
Slide 14: Phase 1a/b Clinical Plan
14 Phase 1la/b Clinical Plan %K Captor ° Therapeutics
Slide 15: Protocol: CT-01-CD-01
Protocol: CT-01-CD-01 A Phase 1, Open-Label, Dose Escalation, and Dose Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CT-01 as Monotherapy and Combination Therapy with Everolimus in Subjects with Intermediate or Advanced Hepatocellular Carcinoma (BCLC Sta
Slide 16: Study design
16 Study design Part 1 - Monotherapy - CT-01 Part 1a: Dose escalation*® Part 1b: Dose expansion — Optional’ RDm + MTD, Ae" DL7 RD,, -1 (20 subjects) DL6 RD,, (20 subjects) (\ Part 2 - Combotherapy - CT-01 + Everolimus (Eve) > Parallel recruitment may start from Part 1a DL3 and Part 2a DL1 (DL. -1+ r
Slide 17: Study design
Study design ▪ Investigational group: patients progressed/intolerant to SoC (ATZ/BEV), or Sorafenib/Lenvatinib ▪ Advanced HCC (BCLC-stage B-C), Child-Pugh A, ECOG 0-1 17
Slide 18: Endpoints in both parts of the study
Endpoints in both parts of the study Primary endpoints: • Incidence of treatment-emergent adverse events (TEAEs), adverse events of special interest (AESIs), serious adverse events (SAEs) • Incidence of DLTs • Changes from baseline in vital signs, physical examinations, electrocardiogram (ECG), echo
Slide 19: Sites recruited to the Study
Sites recruited to the Study Country Site # Institution name Universitätsmedizin der Johannes Gutenberg-Universität GER-003 Mainz GER-005 Universitätsklinikum Bonn Germany GER-002 Universitätsklinikum Leipzig GER-004 Universitätsklinikum Heidelberg Country Site # Institution name FRA-003 Centre Hosp
Slide 20: Prof. Dr. Thomas Berg-Principal Investigator
Prof. Dr. Thomas Berg-Principal Investigator • Head of the Division of Hepatology • Department of Medicine II, Leipzig University Medical Center, Germany • The Former Secretary General of the European Association for the Study of the Liver • Leading the site with Early Phase Clinical Oncology Unit d
Slide 21: Results Highlights
21 Results Highlights %K Captor ° Therapeutics
Slide 22: Key points from the financial results in first half 2024
Key points from the financial results in first half 2024 • Increase in revenues from collaborations from PLN 3,9M to PLN 9,3M • Decrease in grant revenues from PLN 8,0M to PLN 2,5M • Narrowing loss from PLN 43,3M to PLN 19,6M due to focus on lead projects, timing of expenditure on CT-01 costs, and l
Slide 23: Balance sheet and cash position
Balance sheet and cash position Consolidated statement of financial position (PLN, M) Cash position Available funding secured 88,7 (PLN M; as of June 30, 2024): Total : - PLNPLN M PLN 112,6* 67,3 69,2 PLN M 56,5 cash 50,7 56,1 112,6* 56,5 PLN M 56,1 available grants (NCBR; ABM) 26,7 23,8 10,4 8,6 3,
Slide 24: Captor Therapeutics S.A. contact details
ul. Captor Hegenheimermattweg 4123 Contact: 54-427 Duńska Allschwil, Therapeutics Wrocław, investor.relations@captortherapeutics.com 11 Switzerland Poland S.A. GmbH 167A Captor Therapeutics S.A. ul. Duńska 11 54-427 Wrocław, Poland Captor Therapeutics GmbH Hegenheimermattweg 167A 4123 Allschwil, Swi